Natural Health Trends Corp

Natural Health Trends Corp(NHTC)股票分析

$0.764

-0.076 (-9.99%)收盘时

Loading chart…
最高
0.870
开盘
0.856
成交量加权均价
0.78
成交量
129.04K
市值
81.08M
最低
0.700
成交额
100.39K
企业价值/息税折旧摊销前利润(TTM)
0.00

Natural Health Trends Corp. is a direct-selling and e-commerce company. The Company offers a line of NHT Global branded products in categories which include wellness, herbal, beauty, lifestyle and at-home tests. Its wellness products are formulated and designed to meet specific wellness goals, which include nutrition for joint health, antioxidant support, digestive health, heart health, vision health, immune support and cellular health. Its beauty product line includes age-defying and hydrating cleansers, creams, lotions, serums and toners to moisturize, protect and improve the appearance of skin. Its lifestyle products support active, physical and healthy lifestyles, including weight management, and energy-enhancing supplements. Its wellness products include Triotein, Cluster X2, ReStor Silver, and Glucosamine 2200. Its herbal products include LivaPro, Cordyceps Mycelia CS-4, and RespFactor. Its beauty products include Skindulgence Essence Gel, Floraeda Toner and Primer.

AI 分析 of Natural Health Trends Corp (NHTC)

持有

Natural Health Trends Corp (NHTC) is not a strong buy at this moment due to its current price of 0.7642, which is close to its 52-week low of 0.70, indicating a lack of upward momentum. The RSI is at 38.098, suggesting that the stock is nearing oversold territory but has not yet shown signs of a reversal. Additionally, the forward P/E ratio is 13.44, which is reasonable, but the company has reported a significant year-to-date change of -75.19%, reflecting ongoing challenges in revenue generation and profitability. The main risk is the declining net income, which has been negative for the last three quarters, with the latest reported net income of -232,000 USD in Q3 2026.

估值指标

Natural Health Trends Corp(NHTC)当前预期市盈率为 13.44,5 年平均预期市盈率为 2.59。

预期市盈率

高估
5 年均值 P/E
2.59
当前P/E
13.44
高估
8.48
低估
-3.30

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
0.00
当前EV/EBITDA
0.00
高估
0.00
低估
0.00

预期市销率

严重低估
5 年均值 P/S
0.00
当前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 对 NHTC 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%NHTC

$5.32

情景价格

基

基准

基准 · 50%NHTC

$4.76

情景价格

悲

悲观

悲观 · 25%NHTC

$4.39

情景价格

事件时间线

2026-02-17 (ET)

16:50:00

Natural Health Repurchases Shares from George K. Broady Family for $5.9M

2026-02-04 (ET)

09:10:00

Natural Health Trends Corp Q4 Revenue at $9.7M

2025-11-05 (ET)

09:03:54

Natural Health Trends announces Q3 EPS of 4 cents compared to 0 cents in the previous year.

2025-07-30 (ET)

09:02:00

Natural Health Trends reports Q2 EPS 0c vs 2c last year

2025-04-30 (ET)

09:07:07

Natural Health Trends reports Q1 EPS 1c vs 2c last year

资讯

NHTC 常见问题 —— 由 Alphio AI 解答

Natural Health Trends Corp. is a direct-selling and e-commerce company. The Company offers a line of NHT Global branded products in categories which include wellness, herbal, beauty, lifestyle and at-home tests. Its wellness products are formulated and designed to meet specific wellness goals, which include nutrition for joint health, antioxidant support, digestive health, heart health, vision health, immune support and cellular health. Its beauty product line includes age-defying and hydrating cleansers, creams, lotions, serums and toners to moisturize, protect and improve the appearance of skin. Its lifestyle products support active, physical and healthy lifestyles, including weight management, and energy-enhancing supplements. Its wellness products include Triotein, Cluster X2, ReStor Silver, and Glucosamine 2200. Its herbal products include LivaPro, Cordyceps Mycelia CS-4, and RespFactor. Its beauty products include Skindulgence Essence Gel, Floraeda Toner and Primer. It operates in the Consumer Cyclicals sector (WHOLESALE-MISCELLANEOUS NONDURABLE GOODS industry).

Natural Health Trends Corp (NHTC) is not a strong buy at this moment due to its current price of 0.7642, which is close to its 52-week low of 0.70, indicating a lack of upward momentum. The RSI is at 38.098, suggesting that the stock is nearing oversold territory but has not yet shown signs of a reversal. Additionally, the forward P/E ratio is 13.44, which is reasonable, but the company has reported a significant year-to-date change of -75.19%, reflecting ongoing challenges in revenue generation and profitability. The main risk is the declining net income, which has been negative for the last three quarters, with the latest reported net income of -232,000 USD in Q3 2026.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易